Lung Cancer Management (ISSN: 1758-1966)

Description

The strong link between smoking rates and lung cancer incidence has resulted in varying rates of disease within different populations whether on a geographic, socioeconomic or gender basis. What is clear is that, in spite of declining disease rates among some groups in certain developed countries, the disease remains a highly significant global burden. For example, the National Institute of Health estimates that cancer care cost the United States an overall $124.6 billion in 2010, $12.1 billion of which was due to lung cancer.
Surgery, radiotherapy and chemotherapy – alone or in combination – all have a role to play in the treatment of lung cancer. Lung Cancer Management addresses key issues and current understanding in the diagnosis, staging and treatment of disease by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic.
Lung Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances in clinical practice in the field are reported and analyzed by international experts, and the importance of the most recent advances in molecular biology are explained.
The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
Coverage includes:
Biological therapies
Biomarkers
Clinical trials
Comparative effectiveness
Diagnosis and imaging
Molecular biology of disease
Molecular diagnostics
Pharmacoeconomics
Radiotherapy
Risk and prevention
Surgical approaches
Systemic therapies